Loading…

CVS HealthCVSCompetitor analysis, valuation and peers

United States · USD·Health Care›Drugstore Chains

Integrated healthcare company running CVS pharmacies, Aetna health insurance and Caremark pharmacy-benefit management.

Momentum weak 32
Mkt cap
$104B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$1.06B
20-day average traded
Fwd P/E
9.6×
forward earnings
ROIC−WACC
+1.6 pp
WACC 7.0%
Hurdle
-12 pp
Req g minus delivered
Official | Implied
BBB / BBB
agencies · bond market
Next earnings
91 days
17 Feb 2027
Close · USD$81.35
1D-5.2%
1W-9.1%
1M-14.1%
3M-13.1%
6M-12.8%
YTD+4.3%
1Y+5.5%
ATR %3.9%
Beta0.01
52w lowhigh26.5% off high

What CVS Health does

Integrated healthcare company running CVS pharmacies, Aetna health insurance and Caremark pharmacy-benefit management.

Earns from four linked businesses: pharmacies; Caremark, which negotiates drug prices for employers and insurers and earns fees and rebates; Aetna's insurance premiums; and primary-care clinics bought through Oak Street Health in 2023. Insurance and pharmacy benefits make up most of the revenue.

Products and services

  • Retail/specialty pharmacy
  • Aetna health insurance
  • Caremark pharmacy benefit management
  • Primary care (Oak Street, MinuteClinic)

Customers

  • Patients/consumers
  • Employers and health plans
  • Medicare/Medicaid beneficiaries

Where it sits in the supply chain

  • Healthcare
  • Pharmacy & health insurance
  • Retail pharmacy, PBM & insurance

What could go right

  • Aging population healthcare demand
  • Integrated care-delivery cross-sell

What could go wrong

  • PBM regulatory/reimbursement pressure
  • Retail pharmacy margin compression

Moat: narrow (scale, distribution, switching costs). Vertical integration across pharmacy, PBM and insurance creates scale advantages and data lock-in.

Headquarters: Woonsocket, Rhode Island, US · Founded: 1963 · Employees: 300,000

Named competitors

CVS Health at a glance

Size CVS Health (CVS) is a United States Health Care company (Drugstore Chains) with a market value of $104B, the 120th largest of 3,085 United States companies the cockpit tracks. Shares closed at $81.35 on 18 Nov 2026.

Performance Over six months the shares fell 12.8%, against +22.5% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 6.8% over the last twelve months (peer median +8.5%); the operating margin is 3.6% (peer median 20.4%).

Valuation It trades at 9.6× forward earnings against a peer median of 17.7× (3rd cheapest of 20).

Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -12 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.6 points above its cost of capital (7.0% WACC).

Credit CVS Health has 36 bonds outstanding ($55.8B), rated BBB by the agencies and trading like BBB at a weighted spread of 101 bp.

Short interest Short interest is 1.4% of the free float (30 Oct 2026).

Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 123CVS 87
Six months, rebased to 100: CVS Health against the median of its 20 peers (local-currency closes).

CVS Health financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$421B$402B$373B$358B$323B
Revenue growth—+8%+4%+11%—
Gross profit$59.8B$55.4B$51.3B$54.9B$54.8B
EBITDA$19.8B$17.1B$14.5B$19.9B$20.8B
Net income$11.0B$1.77B$4.61B$8.34B$4.31B
Free cash flow$15.6B$7.81B$6.33B$10.4B$13.4B
Capital expenditure$3.14B$2.83B$2.78B$3.03B$2.73B
Total debt$75.3B$80.0B$82.9B$79.4B$70.7B

Quarterly statements and history in the cockpit →

CVS Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%-10%0%+10%HCAREGNSYKBMYELVMCKMDTVRTXMRNACIISRGPFEDHRCORCAHBSXEWABTARGXBDXCVS6-month return →1-month return →
Up and to the right = strong over both horizons. CVS Health is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%10×20×30×HCAREGNSYKBMYELVMCKMDTVRTXCIISRGPFEDHRBSXEWABTARGXBDXCVSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CVS Health is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%HCAREGNSYKBMYMCKISRGDHRARGXCVSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. CVS Health is the large dot.

CVS Health competitors and peer comparison

Head to head with its named competitors (CVS vs UNH vs CI vs COR)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
CVS Health CVS$104B-13%+7%4%9.6×-3.8%
UnitedHealth UNH$314B-8%+3%5%15.4×3.1%
Cigna CI$75.2B+1%+7%4%8.8×-3.8%
Cencora COR$66.5B+32%+5%1%17.7×-1.2%

How CVS Health compares with its peers

Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CVS Health against its 20 peers (data as of 18 Nov 2026)
MeasureCVSPeer medianRank in peer set
1-month return-14.1%+2.1%2nd lowest of 21
6-month return-12.8%+22.5%2nd lowest of 21
Distance from 52-week high-26.5%-10.5%4th lowest of 21
Revenue growth (TTM)+6.8%+8.5%8th lowest of 21
Operating margin3.6%20.4%5th lowest of 21
Forward P/E9.6×17.7×3rd cheapest of 20
Growth the price implies (Req g, 7 yrs)-3.8%5.8%5th least demanding of 20
Growth delivered (Del g)+8.4%+9.5%8th lowest of 20
Hurdle (Req g minus delivered)-12.2 pp-6.0 pp6th least demanding of 20
ROIC minus cost of capital+1.6 pp+8.5 pp5th lowest of 18
Net debt / EBITDA3.0×1.6×2nd most indebted of 18
Bond spread101 bp78 bp2nd widest of 17

Peer table

Peer set: Sector in the same market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
CVS Health CVSUnited States$104B-13%+7%4%9.6×-3.8%+8.4%
HCA Healthcare HCAUnited States$99.5B+20%+6%15%15.6×3.1%+8.0%
Regeneron Pharmaceuticals REGNUnited States$97.8B+46%+19%30%11.8×-1.1%+11.0%
Stryker SYKUnited States$121B-1%+8%25%19.9×10.7%+11.8%
Bristol Myers Squibb BMYUnited States$122B+3%+4%33%9.2×-13.1%+2.5%
Elevance Health ELVUnited States$86.6B+2%+4%4%13.9×4.3%+10.3%
McKesson MCKUnited States$125B+44%+8%2%22.1×-5.5%+11.1%
Medtronic MDTUnited States$129B+30%+10%20%16.8×9.1%+3.8%
Vertex Pharmaceuticals VRTXUnited States$136B+25%+11%35%28.5×6.2%+14.2%
Moderna MRNAUnited States$79.6B+309%+13%-116%n/an/an/a
Cigna CIUnited States$75.2B+1%+7%4%8.8×-3.8%+11.4%
Intuitive Surgical ISRGUnited States$146B-6%+20%32%34.8×29.6%+18.2%
Pfizer PFEUnited States$160B+9%+1%26%9.9×-4.3%+8.5%
Danaher DHRUnited States$161B+34%+6%21%25.1×20.8%+2.0%
Cencora CORUnited States$66.5B+32%+5%1%17.7×-1.2%+9.5%
Cardinal Health CAHUnited States$64.3B+40%+10%1%21.1×7.8%+9.4%
Boston Scientific BSXUnited States$63.3B-23%+9%21%14.1×5.8%+15.2%
Edwards Lifesciences EWUnited States$60.5B+27%+13%29%32.3×17.1%+6.7%
Abbott Laboratories ABTUnited States$181B+18%+10%14%17.9×16.5%+5.1%
argenx SE Sponsored ADR ARGXUnited States$59.1B+17%+71%29%29.0×11.7%+151.4%
Becton Dickinson BDXUnited States$58.9B+48%-7%16%16.3×-1.6%+0.3%

CVS Health bonds and credit

CVS Health has 36 bonds outstanding with $55.8B face value. The agencies rate it BBB; its bonds trade like BBB. Weighted yield 5.92%, a spread of 101 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are CVS Health's main competitors?
Named competitors: UnitedHealth Group (UNH), Walgreens Boots Alliance (private or unlisted), Cigna (CI), Cencora (COR). The cockpit's measured peer set (sector in the same market, nearest in size) also includes HCA Healthcare (HCA), Regeneron Pharmaceuticals (REGN), Stryker (SYK), Bristol Myers Squibb (BMY), Elevance Health (ELV), McKesson (MCK).
Is CVS Health expensive compared with its peers?
On forward p/e it trades at 9.6× against a peer median of 17.7×, 3rd cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -12 pp: the price already allows for a slowdown.
How has CVS Health stock performed?
Over six months to 18 Nov 2026 the shares returned -12.8% against +22.5% for the median peer; over one year +5.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.